CompletedNot applicableNCT02526966
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Principal Investigator
- Christophe MARIAT, MD PhD, M.DCHU de SAINT-ETIENNE
- Intervention
- blood sample(biological)
- Enrollment
- 68 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2014
Study locations (15)
- CH d'ANNECY, Annecy, France
- CH d'ANNONAY, Annonay, France
- CH de BOURG EN BRESSE, Bourg-en-Bresse, France
- CH de CHAMBERY, Chambéry, France
- CHU de CLERMONT-FERRAND, Clermont-Ferrand, France
- CHU de DIJON, Dijon, France
- CHU de GRENOBLE, Grenoble, France
- CH du PUY EN VELAY, Le Puy-en-Velay, France
- Hôpital Edouard. HERRIOT, Lyon, France
- Centre Hospitalier de Lyon Sud, Pierre-Bénite, France
- CH de ROANNE, Roanne, France
- Hôpitaux Drome Nord, Romans, France
- CHU de SAINT-ETIENNE, Saint-Etienne, France
- CH de VALENCE, Valence, France
- Clinique du TONKIN, Villeurbanne, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02526966 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07571746A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseAstraZeneca
- RECRUITINGPHASE2NCT07146906A Study to Assess the Effects of Zigakibart on IgA Nephropathy.Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07375758A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.Beijing Mabworks Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University